MaxCyte (MXCT) CFO receives 187,500 restricted stock units in equity grant

Q: What insider transaction did MXCT CFO Parmeet Ahuja report on this Form 4?

Parmeet Ahuja, Chief Financial Officer of MAXCYTE, INC. , reported receiving 187,500 restricted stock units (RSUs) of Common Stock. Each RSU is a contingent right to one share, granted at no purchase price as part of his equity compensation arrangement.

Q: How many MAXCYTE (MXCT) shares are covered by Parmeet Ahuja’s RSU grant?

The RSU grant to Parmeet Ahuja covers 187,500 shares of MAXCYTE Common Stock. Each RSU corresponds to one share, giving him a future right to receive these shares as they vest over the disclosed schedule in the filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Ahuja Parmeet reported acquisition or exercise transactions in this Form 4 filing.

MAXCYTE, INC. Chief Financial Officer Parmeet Ahuja reported an equity award of 187,500 shares of Common Stock in the form of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of common stock at no purchase price.

According to the filing, 25% of the RSUs will vest on March 30, 2027, and the remaining RSUs will vest in three equal annual installments after that date, subject to Ahuja’s continued service with the company through each vesting date. Following this grant, Ahuja directly holds 187,500 shares reported in this Form 4.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ahuja Parmeet

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	187,500	$0.00	--

Holdings After Transaction: Common Stock — 187,500 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

RSU grant size: 187,500 shares Grant price per share: $0.0000 per share Shares held after transaction: 187,500 shares +1 more

4 metrics

RSU grant size 187,500 shares Restricted stock units of Common Stock granted to CFO

Grant price per share $0.0000 per share Reported transaction price for RSU award

Shares held after transaction 187,500 shares Total Common Stock reported as directly owned post-grant

Initial vesting date March 30, 2027 25% of RSUs vest on this date, per footnote

Key Terms

restricted stock units ("RSUs"), contingent right, vesting, continued service

4 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

vesting financial

"Twenty-five percent (25%) of the RSUs shall vest on March 30, 2027, and the remainder shall vest..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continued service financial

"..., subject to the Reporting Person's continued service to the Issuer through each vesting date."

Form 4 Insider Transactions: What Each Field Means →

04/17/2026 - 04:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ahuja Parmeet

(Last)

(First)

(Middle)

C/O MAXCYTE, INC.

9713 KEY WEST AVENUE, SUITE 400

(Street)

ROCKVILLE

MARYLAND

20850

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAXCYTE, INC. [ MXCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/15/2026		A		187,500⁽¹⁾	A	$0	187,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Twenty-five percent (25%) of the RSUs shall vest on March 30, 2027, and the remainder shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

	/s/ Parmeet Ahuja	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MXCT CFO Parmeet Ahuja report on this Form 4?

Parmeet Ahuja, Chief Financial Officer of MAXCYTE, INC., reported receiving 187,500 restricted stock units (RSUs) of Common Stock. Each RSU is a contingent right to one share, granted at no purchase price as part of his equity compensation arrangement.

How many MAXCYTE (MXCT) shares are covered by Parmeet Ahuja’s RSU grant?

The RSU grant to Parmeet Ahuja covers 187,500 shares of MAXCYTE Common Stock. Each RSU corresponds to one share, giving him a future right to receive these shares as they vest over the disclosed schedule in the filing.

What is the vesting schedule for Parmeet Ahuja’s 187,500 MXCT RSUs?

The filing states that 25% of the RSUs will vest on March 30, 2027. The remaining RSUs will then vest in three equal annual installments thereafter, conditioned on Ahuja’s continued service with MAXCYTE through each applicable vesting date.

Does Parmeet Ahuja pay anything for the 187,500 MAXCYTE RSUs?

According to the Form 4, the RSUs were granted at a price of $0.0000 per share. This indicates the award is compensation-based, not a market purchase, giving him contingent rights to shares without an out-of-pocket purchase price.

How many MAXCYTE shares does Parmeet Ahuja hold after this RSU grant?

The Form 4 reports that, following the RSU grant, Parmeet Ahuja holds 187,500 shares of MAXCYTE Common Stock directly. This total reflects the newly awarded RSUs reported in this filing as his direct beneficial ownership position.